StemCell Therapy

Global Psoriatic Arthritis Treatment Market: Overview

The demand within the global psoriatic arthritis treatment market has been rising on account of advancements in the field of healthcare and biosimilar analysis. The occurrence of psoriatic arthritis can place an extremely negative toll on the overall health of individuals. This is because psoriatic arthritis is more severe than any other form of arthritis. Under psoriatic arthritis, patients suffering from a skin condition called psoriases start to exhibit extreme symptoms of arthritis. This results in excessive pain, uneasiness, and discomfort for the sufferer, often necessitating emergency dosage of steroids. Hence, there is a dire need to ensure that psoriatic arthritis is controlled which in turn gives an impetus to the growth of the global market. The revenue scale of the global psoriatic arthritis treatment market shall improve alongside advancements in the field of geriatric care.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5495

There is no permanent treatment for psoriatic arthritis, and it can only be controlled with proper medication. The discomfort suffered by people affected with psoriatic arthritis is abysmal. Owing to the aforementioned factors, the global psoriatic arthritis treatment market is projected to attract the attention of the medical fraternity in the years to follow. The demand for psoriatic arthritis is projected to reach new heights in the years to follow.

The global psoriatic arthritis treatment market can be segmented on the basis of the following parameters: drug class, route of administration, and region. Based on drug class, the global psoriatic arthritis treatment market can be segmented into Disease-modifying Antirheumatic Drugs (DMARDs), Nonsteroidal Antiinflammatory Drugs (NSAIDs), and biologics. Based on route of administration, the global psoriatic arthritis treatment market can be segmented into orals, topical, and injectables.

Global Psoriatic Arthritis Treatment Market: Notable Developments

Several advancement in the competitive landscape have become a key characteristic of the global psoriatic arthritis treatment market in recent times.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=5495

Global Psoriatic Arthritis Treatment Market: Growth Driver

The occurrence of psoriatic arthritis is preceded by the severity of psoriasis in individuals. Hence, the field of dermatology needs to be work in conjunction with other medical departments in order to treat and control psoriatic arthritis. Hence, the global psoriatic arthritis treatment market shall expand alongside advancements in the field of dermatology. Furthermore, the availability of over-the-counter drugs for treatment of psoriatic arthritis propelled demand within the global market.

The joints suffer severe pain during psoriatic arthritis treatment, and the patients need to be quick recourse treatments. In a lot of cases, psoriatic arthritis poses a risk of permanent damage of joints. For this reason, the demand for psoriatic arthritis treatment has been rising at a stellar pace.

Global Psoriatic Arthritis Treatment Market: Regional Outlook

On the basis of geography, the global psoriatic arthritis treatment market can be segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Asia Pacific. The psoriatic arthritis treatment market in North America is expanding alongside advancements in the field of regional healthcare.

The global psoriatic arthritis treatment market can be segmented as:

Route of Administration

Read Comprehensive Overview of Report @https://www.tmrresearch.com/psoriatic-arthritis-treatment-market

View post:
Psoriatic Arthritis Treatment Market Competitive Landscape Analysis with Forecast by 2028 - 3rd Watch News

Last week I wrote about arthritis, the type that happens as we age and our joints become victim to the usual wear and tear that comes with use.

Following on from that, Id like to talk about some of the other types of arthritis that can affect us.

Rheumatoid arthritis is not caused by wear and tear, but rather our own immune system attacking the joints. Unlike osteoarthritis, rheumatoid arthritis is not something that comes to most of us as we age although if you do suffer with it, then your joints may become gradually worse over time.

The immune system is triggered into acting as though we are being attacked at the site of the joints, causing swelling, redness and inflammation. This inflammation can be quite aggressive and in some cases the swelling itself causes the joint to mis-align, becoming painful and deformed permanently.

A common area for this to happen is in the finger and wrist joints. The fingers can start to bend in ways that are abnormal, making every day tasks like opening jars difficult and painful.

If you have rheumatoid arthritis, then nutrients like glucosamine, MSM, collagen and chondroitin are not the remedies to turn to. While these nutrients are used to repair and protect joints over time, in rheumatoid arthritis, the most important method of protecting your joints is to manage the inflammation and keep it under control.

Herbs that manage inflammation are too numerous to list in a single article but there are a few that are very specific to joint pain. One of these is devils claw, a herb that I was taught in my early years of training is especially helpful for arthritis that has begun to warp the fingers.

Since people with RA (rheumatoid arthritis) can end up with their fingers bent and curled at the joint, I was taught to remember devils claw for hands that are curled like claws.

Not everyone with RA has joint damage to this extent and managing the condition can help to avoid serious or more permanent changes to the joints. Devils claw is an anti inflammatory herb which acts by blocking some of the chemical pathways that lead to inflammation.

By blocking these pathways, the inflammatory response of the immune system is reduced, leading to less pain and a longer life for joints that would otherwise be damaged.

Unlike other pain medicines, devils claw should be taken over a period of eight weeks before you assess how well it is or isnt working for you. Rather than a temporary action that gets to work immediately but fades after a few hours, the effect of devils claw is gradually built up. Once it is working the anti inflammatory effect should be consistent and it is safe to take long term.

In a trial over eight weeks, patients with various rheumatic conditions were given a dose of devils claw. Results concluded that pain was significantly reduced by up to 58 per cent, so even though it can take a while to get to work, it is worth sticking out that eight week period.

If you suspect that you have an arthritic condition, getting a clinical diagnosis from your GP is very important. Your doctor can provide a blood test if they suspect that your arthritis is rheumatoid. If you test positive, then treatment can be provided that is specific to your condition, making it more likely to be effective and lengthening the life of your joints.

In some cases, autoimmune medicines are offered to stop your body from attacking itself. A big concern, especially during current times, of people on immune suppressants is that they may not be as able to fight off colds, bugs and viruses as they otherwise would be.

In this instance, you can help yourself with herbs but it is important to avoid anything stimulating like echinacea which can work against your medicine.

Instead, take immune nutrients like zinc, vitamin C and vitamin D to support your body more gently through nourishment.

For more information on arthritis and ways to manage it naturally, contact Nicola at her clinic on 01524 413733.

Read the original post:
Medical herbalist Nicola Parker explains the treatment for different types of arthritis - Clitheroe Advertiser

A condition that has no cure. A condition that has very generic risk factors. And, a condition that could make your life living hell.

Rheumatoid Arthritis (RA), is a condition that causes a person's immune system to attack their body cells, leading to severe damage to bones and cartilage. Symptoms include joint pain, weakness and inflammation around joints. RA affects over 400,000 people in the UK and is an autoimmune disease. As mentioned, an overactive immune system leads to it, but the reason behind such activity is something we yet do not know.

RA has no cure so far. And so, the only way to treat it is by giving immunosuppressants (medicine that reduces the activity of the immune system) or physiotherapy to ease joint pain. However, AI has been introduced to the RA landscape and so far, there have been studies on how it could help detect signs of RA early on, so minimal damage is done.

A study in 2019 from an American medical journal, JAMA Network Open was conducted, with a cohort of 116 and 117 RA patients. These were across a university hospital and a safety-net hospital. The model aimed to predict disease activity for a patient the next time they visited an RA clinic. Though the way of measurement is quite complex, the way the model performed was measured by calculating the area underneath a receiver operating characteristic curve (AUROC). This is a graphical plot that shows how well a system can distinguish between two groups. The conclusion came out to be 0.91 (university hospital) and 0.74 (safety-net hospital). Though to us, these results may not seem as much, to the researchers they showed that forecasting RA is possible with AI if data and AI models can be shared across hospitals.

Another very important advancement in the RA field was accomplished by healthcare start-up Living With, at the University of Bath, alongside the Royal United Hospitals Bath NHS Foundation Trust (RUH). A flare-up in medical terms is where the symptoms for a disease get worse, and that's when the disease is most active. These flare-ups can be difficult to predict. Living With have developed a Flare Profiler using smartphone technology and thermal imaging to stop the long-term harm from RA. A side-goal for Living With, is for RA patients to not always see a consultant each time they want to know how their body is coping up. They could see a specialist nurse, who would just need to interpret the data coming from the profiler. The profiler comes in the form of an app and will use AI to recognise disease patterns and then provide different routes for treatment.

Link:
How AI Is Slowly, But Steadily, Affecting The Treatment Of Rheumatoid Arthritis. - AI Daily

Pfizers immunology portfolio includes the JAK inhibitor Xeljanz and a pipeline of five mid- to late-stage experimental drugsa huge stable of assets that seems well-positioned to fuel strong growth over the next five years.

But one influential Wall Street firm took a deep dive into that immunology portfolio and found a troublesome undercurrent that made its analysts wonder just how much it will really contribute to Pfizers future growth.

Analysts at SVB Leerink warned clients in a note on Wednesday that our review of the competitive landscape suggests Pfizers compounds could be beaten on speed to market, or better clinical data, in nearly all indications.

One challenge is that Pfizer is heavily dependent on JAK inhibitors, SVB Leerink said. Xeljanz is approved to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. Pfizers nearest-term prospect in its immunology portfolio is JAK inhibitor abrocitinib, which is in phase 3 trials to treat atopic dermatitis.

The SVB Leerink analysts expect abrocitinib to be bringing in $2 billion in sales by 2027. Another phase 3 JAK inhibitor, PF-06651600 for alopecia, should peak at $500 million a year, they added.

But abrocitinib will likely carry the Black Box warning that the FDA has slapped on the JAK class, which warns of a high risk of serious infections, cancer, blood clots and other issues. That warning should relegate the drug to [second-line] behind Regenerons Dupixent until physicians gain experience and confidence in the product.

RELATED: AbbVie's Rinvoq scores pivotal trial win in eczema. But do dermatologists trust JAK inhibitors?

Dupixent is far from the only rival drug that could pose challenges for Pfizer. AbbVies JAK inhibitor Rinvoq, approved to treat rheumatoid arthritis last year, could score a green light in atopic dermatitis before abrocitinib does, SVB Leerink analysts predicted. In this situation, abrocitinib would not offer as much safety as Dupixent, or the efficacy of Rinvoq, and we'd expect it to struggle to gain market share, they said.

Last month, AbbVie released clinical trial data showing that Rinvoq was better than placebo at producing a 75% drop in atopic dermatitis symptoms and clear or almost clear skin after 16 weeks. At the time, SVB Leerink predicted Rinvoq could become the standard of care for patients who dont do well on Dupixent.

Pfizer has produced some positive data of its own, though it hasnt yet been impressive enough to convince analysts that abrocitinib will shoot to the top of the competitive class of JAK inhibitors. Last October, Pfizer said the drug produced clear or almost clear skin in 43.8% of eczema patients participating in a phase 3 trial, versus 7.9% of those taking a placebo. More recently, Pfizer reported a statistically significant improvement in symptoms among teenagers in a phase 3 trial.

RELATED: Pfizer's JAK abrocitinib comes through in teen eczema test

Pfizer is also testing a TYK2 inhibitor in psoriasis, but its facing stiff competition there, too. Bristol Myers Squibb is working on a TYK2 inhibitor, BMS-986165. SVB Leerink analysts pointed out that BMS recently posted clinical trial data suggesting its drug could offer double the effectiveness of Otezla, the drug BMS had to sell to Amgen in order to consummate its Celgene takeover. Add to that the fact that Pfizer is roughly two years behind BMS, and its hard to imagine it could make much of a mark in TYK2 inhibition, SVB Leerink said.

All in all, the analysts are projecting that Pfizers immunology sales will be flat this year and next at about $4.3 billion. From there, sales could grow 5% to 10% a year, they saidbut only if the companys JAK inhibitors are successful.

Ultimately, though, Pfizer may not be well-positioned to grab a significant piece of a rapidly growing market. Global JAK inhibitor sales could grow from $2.7bn to $19.3bn with additional launches and indications, SVB Leerink predicted, but if it materializes, Pfizer might get only a small share.

Follow this link:
Pfizer may have a lot going on in immunology, but all its drugs could be beaten by rivals: analyst - FiercePharma

Global Rheumatoid Arthritis Stem Cell Therapy Market Growth Projection

The new report on the global Rheumatoid Arthritis Stem Cell Therapy market is an extensive study on the overall prospects of the Rheumatoid Arthritis Stem Cell Therapy market over the assessment period. Further, the report provides a thorough understanding of the key dynamics of the Rheumatoid Arthritis Stem Cell Therapy market including the current trends, opportunities, drivers, and restraints. The report introspects the micro and macro-economic factors that are expected to nurture the growth of the Rheumatoid Arthritis Stem Cell Therapy market in the upcoming years.

The report suggests that the global Rheumatoid Arthritis Stem Cell Therapy market is projected to reach a value of ~US$XX by the end of 2029 and grow at a CAGR of ~XX% through the forecast period (2019-2029). The key indicators such as the year-on-year (Y-o-Y) growth and CAGR growth of the Rheumatoid Arthritis Stem Cell Therapy market are discussed in detail in the presented report. This data is likely to provide readers an understanding of qualitative and quantitative growth prospects of the Rheumatoid Arthritis Stem Cell Therapy market over the considered assessment period.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

The report clarifies the following doubts related to the Rheumatoid Arthritis Stem Cell Therapy market:

Segmentation of the Rheumatoid Arthritis Stem Cell Therapy Market

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Vital Information Enclosed in the Report

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Read more:
Rheumatoid Arthritis Stem Cell Therapy Market Trends, Outlook and Opportunity Analysis 2018 to 2028 - Cole of Duty

The next few months could bring the first gene therapy for hemophilia, a new type of multiple myeloma drug and an additional treatment option for a devastating muscular condition.

The Food and Drug Administration is set to make decisions on approval of all three, as well as on a closely watched arthritis pill and the first oral drug for spinal muscular atrophy, between July and September.

A regulatory OK for Roctavian, BioMarin Pharmaceutical's experimental hemophilia A treatment, would be a particularly significant milestone the first gene therapy for one of the world's most well-known inherited diseases. Approvals for Roche's risdiplam, NS Pharma's viltolarsen, Gilead's filgotinib and GlaxoSmithKline's belantamab mafodotin would also be notable.

The list of experimental drugs slated for the FDA's review during the third quarter was originally longer, but the agency cleared three targeted cancer therapies months ahead of schedule. (Seattle Genetics' Tukysa, Novartis' Tabrecta and Eli Lilly's Retevmo were all approved in April and May.)

Even as it's moved quickly to approve new drugs, the FDA has acknowledged the strain resulting from the work the agency is doing to oversee COVID-19 vaccine and drug development. So far, new drug reviews haven't been heavily affected, but the FDA has warned they could be slowed.

The five experimental drugs are listed in order of the currently scheduled date by which the FDA has agreed to make a decision on approval.

Around a dozen drugmakers are developing multiple myeloma treatments that target a protein known as BCMA, which is found on nearly all malignant cells. GlaxoSmithKline looks to be in a position to get there first.

GSK's drug, called belantamab mafodotin, is an antibody-drug conjugate, designed to bind to the BCMA target and deliver a small chemotherapy payload to attack cancerous cells. The conjugate approach is employed by Seattle Genetics' Adcetris and Roche's Kadcyla for other types of blood cancer.

Behind belantamab mafodotin, however, several other BCMA-targeting therapies are nearing key milestones, including a CAR-T cell therapy from Bristol-Myers Squibb and Bluebird bio, as well as a bispecific antibody from Regeneron.

They would trail belantamab mafadotin if the GSK drug is approved by the FDA's target decision date sometime this month. But the rival therapies could potentially offer advantages in greater effectiveness or more manageable side effects. Notably, balantamab mafadotin is associated with an eye-related side effect called keratopathy.

The FDA's decision to approve Sarepta Therapeutics' Exondys 51 for Duchenne muscular dystrophy in 2016 was one of the most controversial in the agency's recent history. The drug, a type of genetic treatment known as "exon-skipping," was the first specifically cleared for patients with DMD.

Approval late last year of Sarepta's second drug Vyondys 53 for a different segment of DMD patients was nearly as dramatic, with the FDA reversing an initial rejection after the company appealed to more senior agency officials.

The FDA's review of a DMD treatment developed by NS Pharma, a little-known subsidiary of Japan's Nippon Shinyaku, promises to be less eventful.

NS' drug, called viltolarsen and designed to treat the same group of DMD patients as Vyondys 53, works similarly to both of Sarepta's drugs. Study results published in JAMA Neurology this past May suggest it might even work better than Vyondys 53, although comparing drugs across trials can be misleading.

Like Sarepta, however, NS is offering the FDA limited evidence to go on. The study supporting the drugmaker's application primarily tested whether viltolarsen increased the production of a key protein that's largely missing in children with DMD and, notably, lacked a placebo comparison.

Having cleared Exondys 51 and then Vyondys 53, however, the FDA seems to have signaled it will accept early data as compelling enough to merit approval. A decision is expected sometime in August.

For Gilead and partner drugmaker Galapagos, much is riding on filgotinib. The drug is at the center of a research collaboration between the two companies, first inked in 2015 and then expanded with a $5.1 billion pact last year.

Part of a class of drugs called JAK inhibitors, filgotinib is aimed first at rheumatoid arthritis, a chronic condition for which it will have much competition. Three other JAK inhibitors, Pfizer's Xeljanz, Eli Lilly's Olumiant and AbbVie's Rinvoq, are already approved for rheumatoid arthritis, which is also commonly treated with biologic drugs like Humira.

Some analysts on Wall Street see filgotinib as safer than its JAK-blocking rivals, but the FDA appears to be viewing the risk of blood clots as characteristic of the drug class.

Gilead and Galapagos still think filgotinib can stand out and are counting on an August approval from the FDA to prove it. Clearance for rheumatoid arthritis would be the first step in proving the drug's future for other inflammatory conditions, like Crohn's disease, uveitis and psoriatic arthritis.

An approval for BioMarin's Roctavian would be a significant moment for the still-emerging gene therapy field. The experimental hemophilia A treatment wouldn't be the first gene therapy to gain FDA clearance that milestone went to Luxturna for an inherited form of blindness but it would offer thousands of patients long-lasting control of a disruptive and damaging bleeding disorder.

Roctavian also typifies the substantial benefits gene therapy can offer. Studies showed the treatment largely eliminated bleeding episodes, enabling patients to drastically reduce how much they rely on expensive factor replacement therapy that aids blood clotting. Years later, patients who received the treatment are still largely free of both.

BioMarin has suggested a price for Roctavian as high as $3 million, arguing the drug's value is clear when factor replacement therapy can sometimes cost as much as $1 million per year for severe hemophilia patients.

The company recently detailed follow-up data up to four years post-treatment in patients who were enrolled in early clinical trials. While their levels of blood clotting activity appear to decline over time, they are all still producing the Factor VIII protein that's reduced or missing in patients with hemophilia.

Spinal muscular atrophy, or SMA, is an often-fatal neuromuscular condition that primarily affects infants and children. Until three and a half years ago, there was no treatment.

An approval for Roche and PTC Therapeutics' risdiplam, expected by August 24, would bring to market the third treatment for the disease and the first one taken orally, which may be more convenient for some patients.

The companies have played up risdiplam's advantages compared to Spinraza, the first SMA drug, as well as versus Novartis' gene therapy Zolgensma. Spinraza is administered via a spinal injection, while Zolgensma is infused intravenously for treating infants.

Roche and PTC sought to submit to the FDA study data covering a broad range of patients, from infants to adults and across various levels of disease severity. In doing so, however, they caused the agency to extend its approval review by three months in order to take into account results from a study in less severe adolescents and adults.

View post:
5 FDA approval decisions to watch in the 3rd quarter - BioPharma Dive

Health & FitnessSaturday, July 4, 2020 15:03

By DR FREDRICK OTIENO

Many patients with rheumatic diseases especially those presenting witharthritisreport increasing pain and stiffness during cold seasons.

Tales abound of how some patients can actually predict the onset of rain or cold weather from these symptoms. Whether it is a knee acting up when a rainstorm is on the horizon or, worse yet, a full-fledged rheumatoidarthritisflare when a blizzard hits, many of those with rheumatic diseases swear the weather harms their conditions.

The precise mechanism for this observation is not clearly understood, but it is thought that changes in weather can cause expansion and contraction of tendons, muscles, bones, and scar tissues, resulting in pain in the tissues that are affected byarthritis.

Low temperatures may also increase the thickness of joint fluids, making them stiffer and perhaps more sensitive to pain during movement.

What causes autoimmune diseases?

advertisement

Before addressing what precautions people living with rheumatic diseases can take during the rainy season, it is important to first understand what causes the condition. Anything foreign or toxic to our body are collectively called anti- gens; mostly some form of proteins or carbohydrate.

The immune system identifies these antigens and produces antibodies to get rid of them. Our cells, which are also made up of proteins and carbohydrates, escape the action of these soldiers due to the presence of specific distinguishing features called self-antigens. The immune cells, during their development in the thymus and bone marrow, are exposed to these self-antigens and made tolerant to them.

In a healthy individual, these tolerant cells go on to mature and become cells of the immune system. The body destroys the intolerant ones.

Many times, due to discrepancies in this process of destruction, the autoreactive immune cells escape the surveillance and can cause autoimmune disorders. These discrepancies can be genetic in origin, there could be a mutation in the self-antigens, or excessive and uncontrolled inflammation can lead to an overactive immune system.

Systemic autoimmune disorders occur when the effect of the autoreactive cells are seen all over the body, in conditions like lupus, rheumatoidarthritis, multiple sclerosis, and ankylosing spondylitis.

Arthritisis a common manifestation of most rheumatic diseases and is usually a result of inflammation.

Typical presentation includes:

What precautions can people living with rheumatic diseases take during the cold season?Patients with rheumatic diseases should be on effective treatment that ensures adequate disease control and suppression of inflammation at all times.

Treatments cannot cure autoimmune diseases, but they can control the overactive immune response and bring down inflammation or at least reduce pain and inflammation. These treatments include; non-steroidal anti-inflammatory drugs (NSAIDS), steroids, immunosuppressive drugs, and newer agents called biologic drugs.

Keeping warm: Dressing warmly, avoiding contact with cold water, take a warm shower, use hand gloves, warm bedding, and eat warm foods and beverages to reduce some of the effects seen when there is a drop in ambient temperature.

Exercise regularly: Exercise is crucial for patients living witharthritis. It is known to ease pain, increase strength and flexibility, and boost energy. The tendency during cold weather is for many people to shy off exercises. Patients should however prioritise exercise as this can ease the pain experience.

Dr Otieno is the assistant professor and consultant physician and rheumatologist at Aga Khan University Hospital, Nairobi.

Read more:
Arthritis and the Cold Season - Business Daily

Scientists believe that about 17% of people worldwide dont get enough zinc. This mineral is, however, very important, in particular, with the help of the body formed more than 300 different enzymes.

Who said that a lot of people, about 17% of the population experience zinc deficiency. Among the reasons for this called reducing consumption of animal food, the spread of diarrhoeal disorders and disorders of the intestine, chronic stress.

Zinc performs a very important function when its lack can even cause the fertility this mineral is essential for ovulation, the production of viable sperm, as well as to child bearing and lactation. But this is not all of its functions. Mineral helps preserve collagen in the skin and connective tissues, regulates the production of androgens, which in many cases are the cause of acne and other skin problems, it is involved in the synthesis of leukocytes, thyroid hormones, helps the body regulate the stress response.

Symptoms of zinc deficiency can be diverse, among them we can name:

In the body, zinc is not stored, so it must be regularly supplied in the diet. The daily menu should include seafood, poultry, beef, cocoa, egg yolk, whole seeds of flax, pumpkin and sesame seeds, wheat germ, lentils, almonds, peas, dairy products.

Read the original here:
Skin problems, arthritis, reduced libido Why the body needs zinc and how to get it - The Saxon

The strategy analysis on Global Rheumatoid Arthritis Treatment Market gives insights of market size, trends, share, growth, development plans, Investment Plan, cost structure and drivers analysis. With precise data covering all key aspects of the existing market, this report offers existing data of leading manufacturers. The Rheumatoid Arthritis Treatment market report covers marketing channels and market positioning to potential growth strategies, providing in-depth analysis for new competitors or exists competitors in the Rheumatoid Arthritis Treatment industry. The Report Gives Detail Analysis on Market concern Like Rheumatoid Arthritis Treatment Market share, CAGR Status, Market demand and up to date Market Trends with key Market segments. The report provides key statistics on the market status of the Rheumatoid Arthritis Treatment manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of Rheumatoid Arthritis Treatment market covering all important parameters.

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/166

Global Rheumatoid Arthritis Treatment market 2020-2026: Competitive AnalysisThe Rheumatoid Arthritis Treatment market report designed to provide entry support, customer profile and M&As as well as go-to-market strategy support. We provide a detailed analysis of key players operating in the global Rheumatoid Arthritis Treatment market, including key players such as Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

Scope of Rheumatoid Arthritis Treatment Market:

The Rheumatoid Arthritis Treatment market was valued at XX Million US$ in 2019 and is projected to reach XX Million US$ by 2024, at a CAGR of XX% during the forecast period. In this study, 2019 has been considered as the base year and 2020 to 2024 as the forecast period to estimate the market size for Rheumatoid Arthritis Treatment.

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Rheumatoid Arthritis Treatment Market which would mention How the Covid-19 is Affecting the Rheumatoid Arthritis Treatment Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Rheumatoid Arthritis Treatment Players to fight Covid-19 Impact.

The report also focuses on global major leading industry players of Global Rheumatoid Arthritis Treatment market providing information such as company profiles, product picture and specification, price, capacity, cost, production, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out. With tables and figures helping analyze worldwide Global Rheumatoid Arthritis Treatment market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. In general, the research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position. The report provides detailed information regarding the major factors (drivers, restraints, opportunities, and challenges) influencing the growth of the Rheumatoid Arthritis Treatment market. The Rheumatoid Arthritis Treatment Market Report analyzes opportunities in the overall Rheumatoid Arthritis Treatment market for stakeholders by identifying the high growth segments.

The scope of the report is limited to the application of the type, and distribution channel. The regions considered in the scope of the report include North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy), Other Country (Middle East, Africa, GCC). This report presents the worldwide Rheumatoid Arthritis Treatment market size (value, production and consumption), splits the breakdown (data status 20152019 and forecast to 2024), by manufacturers, region, type and application.

Market segment by Type, the product can be split into:Product Type Segmentation: Epicel, IntegraIndustry Segmentation: Chemical, Cosmetic, Pharmaceutical

The Global Rheumatoid Arthritis Treatment Market report analyses the production of goods, supply, sales, and the current status of the market in a detailed manner. Furthermore, the report examines the production shares and market product sales, as well as the capacity, production capacity, trends in sales, cost analysis, and revenue generation. Several other factors such as import/export status, industrial statistics, demand and supply ratio, gross margin, and industry chain structure have also been studied in the Global Rheumatoid Arthritis Treatment Market report.

The report comprehends precise analytical information related to market forecasts for several upcoming years. The report also includes the particulars about the valuation of macro and microelements significant for the growth of already established Rheumatoid Arthritis Treatment Market contenders and emerging new companies. The report uses SWOT analysis for the growth assessment of the outstanding Rheumatoid Arthritis Treatment Market players. It also analyzes the most recent enhancements while estimating the expansion of the foremost Rheumatoid Arthritis Treatment Market players. Additionally, the key product category and segments along with sub-segments of the global Rheumatoid Arthritis Treatment Market are studied in the global Market research.

What Reports Provides

Full in-depth analysis of the parent market Important changes in market dynamics Segmentation details of the market Former, on-going, and projected market analysis in terms of volume and value Assessment of niche industry developments Market share analysis Key strategies of major players Emerging segments and regional markets Testimonials to companies in order to fortify their foothold in the market.

Further, in the research report, the following points are included along with an in-depth study of each point:

* Production Analysis Production is analyzed with respect to different regions, types, and applications. Here, the price analysis of various Market key players is also covered.* Sales and Revenue Analysis Both, sales and revenue are studied for the different regions of the global market. Another major aspect, price, which plays an important part in the revenue generation is also assessed in this section for the various regions.* Supply and Consumption In continuation of sales, this section studies the supply and consumption of the Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this part.* Other analyses Apart from the information, trade and distribution analysis for the Market, contact information of major manufacturers, suppliers and key consumers are also given. Also, SWOT analysis for new projects and feasibility analysis for new investment are included.

Reasons to Buy:

* Obtain the most up to date information available on the Rheumatoid Arthritis Treatment projects globally.* Identify growth segments and opportunities in the industry.* Facilitate decision-making on the basis of strong historical and outlook of Rheumatoid Arthritis Treatment data.* Develop business strategies with the help of specific insights about the planned and announced Rheumatoid Arthritis Treatment projects globally.* Keep abreast of key new-build Rheumatoid Arthritis Treatment projects globally.* Assess your competitors planned and Rheumatoid Arthritis Treatment projects and capacities.

Additionally, the report is joined by a vital examination of the Rheumatoid Arthritis Treatment marketplace considering progress, part commitments, and future market forecasts. Furthermore, it offers detailed data of vendors including the profile, specifications of a product, sales, applications, annual performance in the industry, investments, acquisitions and mergers, market size, revenue, market share, and more. The report also studies individual regional market size along with country-wise and region-wise market size during the forecast period. The report also understands the export and import, production, and consumption of every particular region holding the highest market share, market size, or CAGR.

Conclusively, This report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Note: *The discount is offered on the Standard Price of the report.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/166

If you wish to find more details of the report or want a Customization Please contacts us. You can get a detailed of the entire research here.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Tel: +1-206-701-6702Email: [emailprotected]

Visit link:
Rheumatoid Arthritis Treatment Market Prognosticated For A Ravishing Growth By 2026 - Daily Research Chronicles

The global Reactive Arthritis Treatment market gives detailed analysis about all the important aspects related to the market. The study on global Reactive Arthritis Treatment market, offers deep insights about the Reactive Arthritis Treatment market covering all the crucial aspects of the market. Moreover, the report provides historical information with future forecast over the forecast period. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. Some of the important aspects analysed in the report includes market share, production, key regions, revenue rate as well as key players.

The study of various segments of the global market are also covered in the research report. In addition to that, for the forecast periods determination of factors like market size and the competitive landscape of the market is analysed in the report. Due to the increasing globalization and digitization, there are new trends coming to the market every day. The research report provides the in-depth analysis of all these trends.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-4982

In addition, the Reactive Arthritis Treatment market report also provides the latest trends in the global Reactive Arthritis Treatment market with the help of primary as well as secondary research methodologies. Additionally, the research report on Reactive Arthritis Treatment market provides a broad analysis of the market which includes market overview, production, producers, dimensions, price, value, growth rate, income, deals, export, consumption, and sales revenue of the global Reactive Arthritis Treatment market. On the other hand, the Reactive Arthritis Treatment market report also studies the market status for the forecast period. However, this will help to increase the marketing opportunities across the world as well as major market providers.

Key Players

Some of the players in reactive arthritis treatment market includes F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Novartis AG, Amgen Inc., Velcura Therapeutics, Inc., Bayer AG, Geri-Care Pharmaceuticals, Merck Sharp & Dohme Corp, UCB S.A., Johnson & Johnson Services, Inc, Bristol-Myers Squibb Company, and AbbVie Inc., among others.

The report covers exhaustive analysis on:

The regional analysis includes:

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

Asia-Pacific (China, India, ASEAN, Australia & New Zealand)

Japan

The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-4982

The Reactive Arthritis Treatment market report also provides helpful insights for every established and innovative players across the globe. Furthermore the Reactive Arthritis Treatment market report offers accurate analysis for the shifting competitive dynamics. This research report comprises a complete analysis of future growth in terms of the evaluation of the mentioned forecast period. The Reactive Arthritis Treatment market report offers a comprehensive study of the technological growth outlook over time to know the market growth rates. The Reactive Arthritis Treatment market report also includes progressive analysis of the huge number of different factors that are boosting or operating as well as regulating the Reactive Arthritis Treatment market growth.

A systematized methodology is used to make a Report on the Global Reactive Arthritis Treatment market. For the analysis of market on the terms of research strategies, these techniques are helpful. All the information about the Products, manufacturers, vendors, customers and much more is covered in research reports. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. Adaptation of new ideas and accepting the latest trends are some the reasons for any markets growth. The Global Reactive Arthritis Treatment market research report gives the deep understanding about the regions where the market is impactful.

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-4982

More here:
Reactive Arthritis Treatment Market to Expand at a Healthy CAGR of XX% Between and 2017 2027 Bulletin Line - Bulletin Line

Ultrasound abnormalities are widespread in patients with rheumatoid arthritis (RA) who are in clinical remission, with no significant association with clinical parameters in remission, according to study results published in Therapeutic Advances in Musculoskeletal Disease.

The study cohort included patients with an established diagnosis of RA who were enrolled in the Biomarkers of Remission in Rheumatoid Arthritis study, which evaluated disease-modifying antirheumatic drug (DMARD) cessation. Patients included this analysis were in clinical remission (Disease Activity Score 28 C-reactive protein [DAS28-CRP], <2.4) and receiving synthetic DMARDs at time of study entry. Patients from the Newcastle Early Arthritis Clinic who were DMARD-naive and undergoing clinical and ultrasonographic evaluation at first presentation with early active RA (DAS28-CRP >2.4) were included in the positive control group and those with seronegative noninflammatory arthralgia (NIA) were included in the negative control group.

Investigators examined the association between clinical parameters and total ultrasound scores with individual dependent variables, which included synovial power Doppler and greyscale, tenosynovial greyscale, and erosions.

Of 294 patients included in the study, 66 with RA were in clinical remission, 146 with early active RA were in the positive control group, and 82 were in the NIA negative control group. Synovial greyscale was common in patients in RA remission and occurred both in patients who did and did not meet the clinical remission criteria irrespective of whether it was the DAS28-CRP <2.4 (n=66) or the American College of Rheumatology/European League Against Rheumatism Boolean criteria (n=40). Other ultrasound abnormalities that occurred frequently included tenosynovial greyscale, erosions, and synovial power Doppler.

There was a significant association between swollen joint count and higher total synovial greyscale score (odds ratio [OR], 1.17; 95% CI, 1.08-1.26; P <.001) in the active RA group. In addition, the investigators observed a significant association between swollen joint count and higher total synovial power Doppler score (OR, 1.20; 95% CI, 1.12-1.30; P <.001). In the NIA group, there were no significant associations between swollen joint count and total synovial greyscale score or synovial power Doppler score. In the RA remission group, there were 6 significant variable-score associations (P <.05) in an adjusted model, but these associations were not significant in the adjusted analysis. In addition, there were no significant associations between the total synovial power Doppler score and clinical parameters in this group.

Study limitations included the reliance on a 7-point scan protocol, the small sample size, and the inclusion of only patients with established disease in the remission group.

Researchers concluded that ultrasound and clinical examination findings do not overlap in RA remission, challenging the proposition of ultrasound-driven management strategies in this setting.

Reference

Baker KF, Thompson B, Lendrem DW, Scadeng A, Pratt AG, Isaacs JD. Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis remission [published online May 11, 2020]. Ther Adv Musculoskelet Dis. doi:10.1177/1759720X20915322

View post:
No Association Between Clinical and Ultrasound Measures of Disease Activity in RA Remission - Rheumatology Advisor

In the early part of the 2014 season, Jason Day missed six weeks with a thumb injury, which he aggravated at that years Masters tournament.

Getty Images

Arnold Palmer is famous for, among other things, his iconic thumbs up to adoring galleries. (Sorry, Phil.) I was lucky enough to call Arnold a good friend; in 2006, we launched the Arnold Palmer Sports Health Center. He had an abiding interest in keeping people healthy and participating in the game he loved.

The thumb is remarkable, and we ask much of it. Gripping a golf club throughout the swing means positioning the thumb at multiple points in space, and that demands great flexibility. This flexibility is provided by two hinge joints and the very agile basilar joint where the thumb plugs into your wrist plus great strength and stability.

This balancing act can create a problem that manifests as friction at the basilar jointaka arthritis. Almost all golfers will eventually get a little degenerative wear and tear arthritis at the thumb joint. Ive operated on several PGA Tour Champions players, but most of us will have milder cases treatable by conservative measures.

Symptoms: Pain and modest swelling at the thumbs base is common; more advanced cases may lead to a decrease in motion. Your hand may feel weakened as discomfort can lead to protecting the thumb from tasks (e.g., opening jars) in which grip power is necessary and potentially painful.

Self-Care: There is a wide range of nonsurgical managementsice, heat, splints and judicious use of over-the-counter anti-inflammatories. Any splint used should include the thumb to help support the basilar joint.

Doctor Visit: A diagnosis will likely entail the doctor loading the thumbs basilar joint and briefly grinding it you may feel the discomfort and mechanical symptoms that accompany joint irregularity. An X-ray can help establish matters definitively. As for treatment beyond splinting and activity modification, a steroid shot can bring temporary relief. As a last resort, a reliable surgery can be performed that allows you to participate in most activities without restriction including golf. Thumbs up to that!

Read this article:
Heres how to deal with one of the most dreaded injuries in golf - Golf.com

Dual-energy computed tomography (DECT) appears to have limited utility for differentiating between gout and calcium pyrophosphate deposition disease (CPPD), according to a German prospective cohort study. Findings were reported at the annual European Congress of Rheumatology, held online this year because of COVID-19.

Dr Valentin S. Schfer

"Differentiation of gout and pseudogout, or CPPD, is sometimes difficult," said presenting investigator Valentin S. Schfer, MD, associate professor of internal medicine and head of the department of rheumatology and clinical immunology at University Hospital Bonn (Germany).

"Arthrocentesis and subsequent polarization microscopy remains the gold standard," he noted. "Novel diagnostic approaches, such as DECT, have recently been validated for gout, but limited data [are] available on the use of DECT in patients with CPPD."

The investigators studied 30 patients: 22 with suspected gout and 8 with suspected CPPD. All underwent arthrocentesis with subsequent polarization microscopy for definitive diagnosis, plus clinical examination, ultrasound examination, conventional radiography, DECT, and assessment of 12 laboratory parameters.

For diagnosis of gout, DECT had a sensitivity and specificity of 59.1% and 100%, respectively, Dr. Schfer reported, noting that this sensitivity falls considerably short of the 90% previously reported for gout (Figure 1).

Figure 1: Gout tophus formation (curved arrow) shown on 80-kV DECT with color-coded overlay showing monosodium urate crystals in green and calcium in blue, as well as articular and juxta-articular osseous erosions (straight arrow).

Corresponding sensitivity and specificity were 90.9% and 75% for ultrasound, 58.8% and 100% for conventional radiography, and 81.8% and 87.5% for the rheumatologists' suspected clinical diagnosis.

For diagnosis of CPPD, DECT had sensitivity of 37.5% and specificity of 81.8%. Corresponding values were 87.5% and 91% for ultrasound, 0% and 94.1% for conventional radiography, and 75.0% and 100% for suspected clinical diagnosis (Figure 2).

None of the 12 laboratory parameters studied uric acid, C-reactive protein, organic phosphate, and leukocytes, among others significantly differentiated between conditions.

Figure 2: DECT image with color-coded overlay shows typical findings of CPPD along the medial and lateral menisci (arrow) and calcium in tissues where it's not usually found (e.g., hyaline cartilage).

"Both ultrasound and suspected clinical diagnosis had higher sensitivities than DECT for gout and CPPD," Dr. Schfer concluded. "Further studies with larger patient cohorts and perhaps modified scan protocols are needed in order to determine the diagnostic utility of DECT in CPPD."

"Noninvasive, accurate methods for distinguishing between gout and CPPD will improve clinical care," Sara K. Tedeschi, MD, MPH, predicted in an interview.

"Arthrocentesis is painful in an acutely inflamed joint, can be difficult to perform on small joints, and is underutilized in clinical practice," she elaborated. And ultrasound is operator dependent and does not quantify crystal volume in and around the joint.

The question addressed by the study is therefore clinically relevant, according to Dr. Tedeschi, a rheumatologist at Brigham and Women's Hospital and assistant professor of medicine at Harvard Medical School, Boston.

However, among the patients with CPPD, the study did not report specific phenotypes (acute inflammatory arthritis, chronic inflammatory arthritis, and osteoarthritis with calcium pyrophosphate deposits), she noted. "It is difficult to draw conclusions about the sensitivity or specificity of DECT for CPPD without this information, especially among just 8 CPPD patients."

In addition, among the patients with gout, the proportion having new-onset disease with flare duration less than 6 weeks and the proportion with tophi were unknown, both of which affected DECT sensitivity in the previous study that reported 90% sensitivity. "Based on the 95% confidence interval in the present study, it is possible that with a larger sample size, DECT sensitivity for gout would have been higher," she pointed out. "We also do not know the DECT software settings, which impact DECT interpretation as positive or negative for the crystal of interest."

Finally, "it would be relevant to know what joints were aspirated and imaged in each group," Dr. Tedeschi said. "For example, if the first metatarsophalangeal (MTP) joint was aspirated and imaged for half of the gout patients but for none of the CPPD patients, that may affect the study interpretation."

The study did not receive any specific funding. Dr. Schfer disclosed a variety of financial relationships with multiple pharmaceutical companies. Dr. Tedeschi disclosed receiving grant support from the National Institutes of Health to study imaging modalities for CPPD, and being first author on a study comparing the sensitivity of DECT, ultrasound, and x-ray for acute CPP crystal arthritis.

Ann Rheum Dis. 2020;79:196. Abstract

This article originally appeared on MDedge.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Read the original post:
DECT Has Mixed Performance in Differentiating Gout vs CPPD - Medscape

Sciepro / Science Photo Library / Getty Images

At first no one believed the mom from Lyme. Polly Murray moved with her family to the Connecticut River town in the late 1950s and within a few years began experiencing mysterious symptoms. There were rashes, migraines, recurring fevers, and severe joint pain including a swollen knee. Over the years her children and even the family dog had similar ailments. Doctors believed it was all in her head, and she agreed to a psychiatrists suggestion to obtain three weeks of inpatient treatment.

By 1975 her two sons were diagnosed with juvenile rheumatoid arthritis, but neighbors had children with similar ailments, and Murray, who died last year, didnt believe the occurrences of this rare condition in children were a coincidence. Murray and another mother reached out to the state Health Department and the Yale School of Medicine.

A few months earlier, a 33-year-old doctor named Allen Steere had started a fellowship in rheumatology at Yale School of Medicine. Steere had spent the previous two years investigating disease outbreaks as an epidemic intelligence officer with the Centers for Disease Control in Atlanta. State officials thought he would be the ideal person to investigate these cases. Steere asked Dr. Stephen Malawista, who headed the rheumatology program at the Yale School of Medicine, for permission to start.

He said, Fine, why dont you take six months and see what you can do? Its now 45 years later, and I and lots of other people are still working on this, Steere says.

Steere, now a professor of medicine at Harvard Medical School and director of translational research in rheumatology at Massachusetts General Hospital, began contacting parents who had children with joint pain, particularly knee pain. Consulting with school nurses in Lyme and surrounding communities, Steere identified 39 children and 12 adults with this unexplained rheumatoid arthritis in Lyme,as well as neighboring Old Lyme and East Haddam. It was clear that they had inflammatory arthritis, he says, but the condition was occurring far too frequently in the area, particularly in children. If you had one child in that Lyme, Connecticut, area that had inflammatory arthritis, maybe thats what youd expect, but not 39. Moreover, there was clustering within certain areas. There were a couple of roads where 1 in 10 children had this type of inflammatory arthritis.

It was apparent that this was something different than had been seen before and described in the medical literature, and we began to call it Lyme arthritis, Steere adds.

Through contact tracing, Steere learned that most cases had occurred in the summer and early fall, and there was no evidence of person-to-person spread. Twenty-five percent of the patients remembered having a strange skin lesion shortly before they developed symptoms. Around the same time, Steere learned from a Danish dermatology resident at Yale that a similar skin lesion called erythema migrans had been known in Europe for years and was caused by a tick bite.

Residents told Steere that as recently as the 1960s there were no ticks, but that the area had been inundated with them by the 1970s. This was due to massive swaths of farmland being converted back to forests, which supported tick and wildlife habitats. By 1976 Steere and his fellow researchers put forth the belief that ticks were responsible for spreading the infection. In 1981 a researcher at the Rocky Mountain Biological Laboratory named Willy Burgdorfer identified the bacteria that causes Lyme. Meanwhile, Steere helped to research early antibiotic treatments for the disease.

Though Lyme emerged from the wilds in Connecticut in and around the 1970s, it was not a new disease, Steere says. There are descriptions of what sounds like Lyme disease in writings from the 1600s and confirmed cases of the disease found in preserved specimens in New England and Europe from the 1800s. The 2010 autopsy of tzi the Iceman, a 5,300-year-old frozen mummy found in the Eastern Alps in the 1990s, revealed he had Lyme disease.

Despite this historical evidence of the condition, conspiracy theories as to its origins are rampant. The most prominent holds that it was a biological warfare agent developed at Plum Island Animal Disease Center, a federal island research facility dedicated to the study of animal diseases 8 miles off the Connecticut coast. Between 1952 and 1954, the island also served as the headquarters for the Army Chemical Corps. The corps hoped to study biological weapons, but according to credible accounts, never truly pursued its work on the island. In addition, Lyme-like conditions were never studied at the island, and there would be records if they were, as the work that takes place on the island is not classified. In addition, tick specimens from 1945 from the South Fork of Long Island were also found to contain the disease, several years before the island facility opened in the 1950s.

Back in the 1970s, Steere says, I knew nothing about Plum Island and nobody thought that Plum Island had anything to do with this. He adds that it wasnt until many years later that he first started hearing conspiracy theories linking Lyme disease to Plum Island.

Jane Marsh, a lifelong Old Lyme resident, recalls her father being one of the first adults to get the disease. Marsh later got the disease, as did everyone in her family. We did not suspect that anything came floating across from there to Old Lyme, she says. She got wind of the conspiracy theory later and, though she never bought into it, Marsh says she knows people in the area who believe it.

The theory has also stretched beyond Connecticut. Last year New Jersey Rep. Chris Smith called for an investigation into whether the Department of Defense experimented with ticks and other insects to deliver biological weapons between 1950 and 1970.

Plum Island isnt the only controversy associated with Lyme disease. Chronic Lyme is a condition many patients believe they have but which the Centers for Disease Control does not recognize, and which Steere has said is overdiagnosed.

Lyme disease is a complex infection, there are no two ways about it, Steere says. Its an illness that without treatment can occur in stages with different manifestations at each stage. People can have neurologic involvement, they can have cardiac involvement, they can have arthritis. But it does not cause everything. There are advocacy groups that have grown up that attribute a much wider spectrum of illness to Lyme disease than is the case in mainstream medicine.

Read more here:
Lyme disease emerged in Connecticut in the 1970s ... then the conspiracy theories started - Connecticut Magazine

COVID-19 remains a mystery in many ways, but as it continues to rampage through the worlds population, some things are becoming more clear. One of them is that cytokine storms a deranged immune response to the virus, in which the body literally attacks its own cells instead of the invading coronavirus appear to be one reason some patients end up extremely ill.

A drug developed in St. Louis aims to combat those cytokine storms. Called ATI-450, it was originally developed by Confluence Discovery Technologies in 2013 with the idea of helping people suffering from autoimmune diseases, particularly rheumatoid arthritis.

But as scientists began to understand the way COVID-19 affects the body, the company realized it could potentially help with the new coronavirus as well.

Were actually in a Phase 2 rheumatoid arthritis study, explained Joe Monahan, Confluence Discovery Technologies executive vice president of research and development, on St. Louis on the Air. That started earlier in the year. But when we saw what was happening with COVID back in January or February, and we started to think about the possibility of both COVID being driven by the cytokine storm in the lung, and [rheumatoid arthritis] being driven by a similar storm of cytokines regulated in the joint, we thought maybe we could do some quick studies in the laboratory to validate that ATI-450 may have an impact on these cytokines in the lung, and in particular things driven by the SARS CoV-2.

Added Monahan, It was the right place at the right time.

And so even as most businesses around St. Louis closed their offices and moved to remote work this spring, Confluence doubled down. With staggered shifts and seven-day workweeks, researchers in its headquarters at Cortexs BioSTL building were able to show strong enough results in the lab to receive FDA approval to begin human trials.

Those are to begin in two weeks at the University of Kansas Medical Center, Monahan said. Thirty-six patients will be given the drug in a double-blind, placebo-controlled study.

The company hopes to show that, by blocking the pathways used to make cytokines, ATI-450 stops the cytokine storms that can be so damaging. Explained Monahan, In so doing, we believe that we would reduce the [acute respiratory distress syndrome] observed in these patients, and reduce the need for mechanical ventilation, decrease the hospital stay, and reduce the mortality.

Listen:

Normally, good results in such a study would mean another three to six years before bringing a drug to market. But Monahan has hopes for a speedier process for ATI-450 when it comes to COVID-19.

If this works really well [against] the disease, and we expand it to more people and it continues to work, I think theres an ability to really shorten those timelines, he said.

Confluence was acquired by Pennsylvania-based Aclaris Therapeutics in 2017, but its researchers remain based in St. Louis. Monahan helped to co-found the company as part of BioSTL after spending 28 years at Pfizer and its legacy companies. The pharmaceutical giant was moving a unit to the Boston area, and rather than relocate, Monahan and some colleagues decided to stay in St. Louis and go out on their own.

We had maybe some different ideas on how to do drug discoveries that we had not been able to do at Pfizer, he said.

St. Louis on the Air brings you the stories of St. Louis and the people who live, work and create in our region. The show is hosted by Sarah Fenske and produced by Alex Heuer, Emily Woodbury, Evie Hemphill, and Lara Hamdan. The audio engineer is Aaron Doerr.

Send questions and comments about this story to feedback@stlpublicradio.org.

Original post:
COVID-19 Treatment Developed In St. Louis To Begin Human Trials - St. Louis Public Radio

Representational Image of Medicine

Researchers at the University of Texas Health Science Center at Houston (UTHealth) in the US are studying the effectiveness of an arthritis drug in treating a type of severe immune overreaction seen in patients with COVID-19 induced pneumonia in Phase 3 clinical trial.

The clinical trial is enrolling patients at the Harris Health System's Lyndon B. Johnson Hospital in Houston, Texas. The Phase 3 study is evaluating the effectiveness of the drug canakinumab, an interleukin-1 (IL-1) blocker approved for the treatment of juvenile rheumatoid arthritis, for preventing cytokine release syndrome (CRS) in COVID-19 patients with pneumonia.

Often referred to as a cytokine storm, CRS is a life-threatening immune reaction caused by the body releasing too many cytokines into the blood at once. Cytokines include a broad category of proteins secreted by the body.

Interleukin-1 serves as the first-line defence for the immune system, alerting other proteins to respond if a virus or bacteria are present. Canakinumab blocks the production of IL-1 protein, which could prevent a possible deadly overreaction of the immune system in COVID-19 patients.

Research has linked a number of COVID-19 deaths to CRS due to damage caused to several major organs.

Roberto C. Arduino, MD, the study's lead investigator and professor of infectious disease at the McGovern Medical School in UTHealth, said this is a time for the HIV research community to utilise the members' expertise in the search for a treatment for coronavirus.

Arduino's research background includes the study of new antiretroviral drugs, treatment strategies, immune activation, and inflammation in the search for an HIV cure.

"The research community truly feels compelled to do something in the search for a viable treatment for COVID-19, and I feel I owe it to my community to offer my expertise," said Arduino, who has led HIV clinical research for 22 years.

Researchers are investigating if canakinumab combined with standard-of-care treatment can increase the chances of survival without ever requiring invasive mechanical ventilation in patients with COVID-19-induced pneumonia.

Over a two-hour period, patients who are enrolled will receive either a 450 mg, 600 mg, or a 750 mg IV dose of canakinumab based on their body weight, UTHealth said in a statement on Monday. Arduino is the study's lead investigator. All participants will be monitored for up to 29 days, or until they are discharged from the hospital. A follow-up will occur at 127 days.

The Weather Companys primary journalistic mission is to report on breaking weather news, the environment and the importance of science to our lives. This story does not necessarily represent the position of our parent company, IBM.

Go here to read the rest:
US Scientists Begin Phase 3 Trial of Arthritis Drug to Study its Effect on COVID-19 - The Weather Channel

Arthritis Ireland has launched a nationwide survey asking people with arthritis to share their experiences of Covid-19. The survey is available online and takes 10-15 mins to complete.

Nearly one million people are living with arthritis in Ireland; many of whom have been severely impacted by the pandemic; for example, due to being immunosuppressed or aged over 70.

The survey includes questions on how the pandemic affected peoples physical and mental health, their access to health services, where they sourced information about the coronavirus, and how their employment and personal finances have been impacted.

Brian Lynch, head of communications and advocacy, said: This research will give us direct insights into how Covid-19 has impacted people living with arthritis. This is a diverse population, but some were extremely medically vulnerable, many were required to cocoon, people had appointments postponed or cancelled. Arthritis is a chronic condition for which there is yet no cure; peoples symptoms, their pain and fatigue didnt disappear during the pandemic.

Lynch said that when they analyse the information, it will help the patient organisation advocate for better services and access to healthcare.

Arthritis is the single biggest cause of disability in Ireland, resulting in significant loss of physical health and function. Inflammatory forms of arthritis are systemic diseases which can affect your whole body. Its vital that our rheumatology service be resourced and structured to best meet the needs of new and existing patients, he said.

At the end of May there were 18,818 people waiting for a rheumatology appointment; 44% of whom were waiting longer than 12 months. There were 68,463 waiting for an appointment with an orthopaedic consultant; 38% of whom were waiting longer than 12 months.

The survey can be accessed via the Arthritis Ireland website,www.arthritisireland.ie.

Read the rest here:
Survey launched on impact of Covid-19 on people with arthritis - TipperaryLive.ie

Synopsis of Global Rheumatoid Arthritis and Lupus Treatments Market Report:

The Rheumatoid Arthritis and Lupus Treatments Market complete overview of the market, covering various aspects product definition, segmentation based on various parameters, and the prevailing market landscape. The report provides a distinct point-of-view through analysing market scenarios to comparative pricing between major players, cost and profit of the specified market regions.

Furthermore, the development of policies and plans as well as manufacturing processes are mentioned to assist in the decision making process. The report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins to justify the stated forecast. To provide an accurate forecast aspects such as regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity have also been thoroughly studied.

Have some queries? Get Free Sample PDF Copy based on Latest Research on Rheumatoid Arthritis and Lupus Treatments Market after the Covid-19 impact: https://www.acquiremarketresearch.com/sample-request/360571/

The report provides a granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. Following are some of the segmentations provided in the report ;

Leading players operating in the global Rheumatoid Arthritis and Lupus Treatments market are: AbbVie, Amgen, Bayer, Biogen Idec, Roche, Johnson and Johnson, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer

Rheumatoid Arthritis and Lupus Treatments Market Growth by Types: Rheumatoid Arthritis Treatments, Lupus Treatments

Rheumatoid Arthritis and Lupus Treatments Market Extension by Applications: Hospitals and Clinics, Ambulatory Surgery Centers, Homecare Settings

The Global version of this report with a geographical classification would cover regions: North America (USA, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Report on Rheumatoid Arthritis and Lupus Treatments Market (covering Covid-19 impacts) at an Impressive Discount! With Corporate Email ID @ https://www.acquiremarketresearch.com/discount-request/360571/

While segmentations have been provided to list down various facets of the Rheumatoid Arthritis and Lupus Treatments market, analysis methods such as S.T.E.E.P.L.E., S.W.O.T., Regression analysis, etc. have been utilized to study the underlying factors of the market. Summarization of various aspects consisted in the report have been listed.

What does this research exactly offer?1.The Rheumatoid Arthritis and Lupus Treatments market shares of every equatorial region as well as market share for every product type with the growth rate for the forecast period has been provided.2.The revenue in terms of valuation and percentage at the end of the forecast period has been well explained with the help of a number of tables and charts.3.The study also includes market share for every separate domain of the Rheumatoid Arthritis and Lupus Treatments market from the beginning of the forecast year to the end of the forecast period.4.The Rheumatoid Arthritis and Lupus Treatments study also encompasses a separate section that included data pertaining to certain important aspects of the market such as vital parameters such as industry chain analysis and analysis of the upstream market and many more.5.Additionally, the report will also include an evaluation of the distribution of the consumer base with a percentage base of which domain will be occupying the most market share during and after the forecast base.

Covid-19 virus has vastly transformed the market and has shaken its position such that it is up for grabs. We at Acquire Market Research help you to achieve your desired market position. While its our primary concern we also provide necessary information regarding the Covid-19 virus and necessary step to stay safe.

Critical doubts Related to Rheumatoid Arthritis and Lupus Treatments Market addressed in the report; What is the CAGR of Rheumatoid Arthritis and Lupus Treatments Market after the effects of Covid-19?What is the current status of markets, with respect to the Rheumatoid Arthritis and Lupus Treatments Market and who are the market leaders?After dispersion of markets, are there any new entrants in the market who are capturing customers at an exponential rate?Competitive strategies of market leaders and their future plans to capture markets?Effects of Covid-19 on the large markets and potential markets of the Rheumatoid Arthritis and Lupus Treatments Market.

For more details on Rheumatoid Arthritis and Lupus Treatments Market Report (Post Covid-19 impact), Ask Our Expert (Use Corporate email ID to Get Higher Priority) @ https://www.acquiremarketresearch.com/enquire-before/360571/

About us:

At Acquire Market Research the database of the company is updated on a daily basis to provide the clients with reports containing the latest trends and in-depth analysis of the industry. While each report initially generated is prepared with a set benchmark of the industry, the reports are customizable to meet the requirements of the client. After careful validation of the report by our expert analysts, the report on Rheumatoid Arthritis and Lupus Treatments Market has been published.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

See original here:
COVID-19 Impact and Recovery Solutions on Rheumatoid Arthritis and Lupus Treatments Market- Business Growth Strategies by Key Players: AbbVie, Amgen,...

Researchers writing in the current issue of Arthritis and Rheumatology report that a blood thinner may have potential as a preventive treatment for osteoarthritis.

Ticagrelor (Brilinta, AstraZeneca) is a P2Y12 platelet inhibitor currently used to prevent stroke and heart attack in patients with acute coronary syndrome or a history of myocardial infarction. It works by increasing the presence of extracellular adenosine which, in turn, regulates the inflammatory processes. Studies in animal models have shown that it is effective in treating osteoarthritis.

In this study, researchers compared the results in patients who were treated with ticagrelor and a second group who was treated with the blood thinner clopidogrel, which does not increase extracellular adenosine concentrations. This was a five-year study that included 7,007 patients who were treated with ticagrelor for an average of 287 days and 14,014 were treated with clopidogrel for an average of 284 days. The study excluded patients with an osteoarthritis diagnosis at baseline. The average patient was 64 years old and most, at 73 percent, were male. Researchers concluded that patients who were treated with ticagrelor had a 29 percent reduced risk of osteoarthritis (estimated a hazard ratio of 0.71 (95% CI 0.64-0.79, p<0.001).

These findings suggest that extracellular adenosine may play an important role in reducing cartilage inflammation and damage, and that it might serve as a therapeutic target for preventing and treating osteoarthritis in humans, wrote researchers who were led by Matthew C. Baker, M.D., of Stanford University. We believe that even this relatively short treatment period may provide protection against developing osteoarthritis over the subsequent years. It is not clear how long this effect may last, as the follow-up period for this study ended at five years, with a relatively small number of patients at risk after three years.

Osteoarthritis affects about 27 million adults in the United States. It was once thought of merely as degeneration of the joints, but today is more often recognized as a disease driven by low-grade inflammation and complex interactions between genes and the environment, Dr. Baker and colleagues wrote. There are no effective treatments to prevent the onset or progression of osteoarthritis, and novel therapies are needed.

REFERENCE

Matthew C. Baker, Yingjie Weng, Robinson H. William, Neera Ahuja, Nidhi Rohatgi. Osteoarthritis risk is reduced after treatment with ticagrelor compared to clopidogrel: a propensity score matching analysis, Arthritis and Rheumatology. First Published: 21 June 2020

Read this article:
Blood Thinner Could Prevent Osteoarthritis - Rheumatology Network

At first no one believed the mom from Lyme. Polly Murray moved with her family to the Connecticut River town in the late 1950s and within a few years began experiencing mysterious symptoms. There were rashes, migraines, recurring fevers, and severe joint pain including a swollen knee. Over the years her children and even the family dog had similar ailments. Doctors believed it was all in her head, and she agreed to a psychiatrists suggestion to obtain three weeks of inpatient treatment.

By 1975 her two sons were diagnosed with juvenile rheumatoid arthritis, but neighbors had children with similar ailments, and Murray, who died last year, didnt believe the occurrences of this rare condition in children were a coincidence. Murray and another mother reached out to the state Health Department and the Yale School of Medicine.

A few months earlier, a 33-year-old doctor named Allen Steere had started a fellowship in rheumatology at Yale School of Medicine. Steere had spent the previous two years investigating disease outbreaks as an epidemic intelligence officer with the Centers for Disease Control in Atlanta. State officials thought he would be the ideal person to investigate these cases. Steere asked Dr. Stephen Malawista, who headed the rheumatology program at the Yale School of Medicine, for permission to start.

He said, Fine, why dont you take six months and see what you can do? Its now 45 years later, and I and lots of other people are still working on this, Steere says.

Steere, now a professor of medicine at Harvard Medical School and director of translational research in rheumatology at Massachusetts General Hospital, began contacting parents who had children with joint pain, particularly knee pain. Consulting with school nurses in Lyme and surrounding communities, Steere identified 39 children and 12 adults with this unexplained rheumatoid arthritis in Lyme, as well as neighboring Old Lyme and East Haddam.

It was clear that they had inflammatory arthritis, he says, but the condition was occurring far too frequently in the area, particularly in children. If you had one child in that Lyme, Connecticut, area that had inflammatory arthritis, maybe thats what youd expect, but not 39. Moreover, there was clustering within certain areas. There were a couple of roads where 1 in 10 children had this type of inflammatory arthritis.

It was apparent that this was something different than had been seen before and described in the medical literature, and we began to call it Lyme arthritis, Steere adds.

Through contact tracing, Steere learned that most cases had occurred in the summer and early fall, and there was no evidence of person-to-person spread. Twenty-five percent of the patients remembered having a strange skin lesion shortly before they developed symptoms. Around the same time, Steere learned from a Danish dermatology resident at Yale that a similar skin lesion called erythema migrans had been known in Europe for years and was caused by a tick bite.

Residents told Steere that as recently as the 1960s there were no ticks, but that the area had been inundated with them by the 1970s. This was due to massive swaths of farmland being converted back to forests, which supported tick and wildlife habitats. By 1976 Steere and his fellow researchers put forth the belief that ticks were responsible for spreading the infection. In 1981 a researcher at the Rocky Mountain Biological Laboratory named Willy Burgdorfer identified the bacteria that causes Lyme. Meanwhile, Steere helped to research early antibiotic treatments for the disease.

Though Lyme emerged from the wilds in Connecticut in and around the 1970s, it was not a new disease, Steere says. There are descriptions of what sounds like Lyme disease in writings from the 1600s and confirmed cases of the disease found in preserved specimens in New England and Europe from the 1800s. The 2010 autopsy of tzi the Iceman, a 5,300-year-old frozen mummy found in the Eastern Alps in the 1990s, revealed he had Lyme disease.

Despite this historical evidence of the condition, conspiracy theories as to its origins are rampant. The most prominent holds that it was a biological warfare agent developed at Plum Island Animal Disease Center, a federal island research facility dedicated to the study of animal diseases 8 miles off the Connecticut coast. Between 1952 and 1954, the island also served as the headquarters for the Army Chemical Corps. The corps hoped to study biological weapons, but according to credible accounts, never truly pursued its work on the island. In addition, Lyme-like conditions were never studied at the island, and there would be records if they were, as the work that takes place on the island is not classified. In addition, tick specimens from 1945 from the South Fork of Long Island were also found to contain the disease, several years before the island facility opened in the 1950s.

Back in the 1970s, Steere says, I knew nothing about Plum Island and nobody thought that Plum Island had anything to do with this. He adds that it wasnt until many years later that he first started hearing conspiracy theories linking Lyme disease to Plum Island.

Jane Marsh, a lifelong Old Lyme resident, recalls her father being one of the first adults to get the disease. Marsh later got the disease, as did everyone in her family. We did not suspect that anything came floating across from there to Old Lyme, she says. She got wind of the conspiracy theory later and, though she never bought into it, Marsh says she knows people in the area who believe it.

The theory has also stretched beyond Connecticut. Last year New Jersey Rep. Chris Smith called for an investigation into whether the Department of Defense experimented with ticks and other insects to deliver biological weapons between 1950 and 1970.

Plum Island isnt the only controversy associated with Lyme disease. Chronic Lyme is a condition many patients believe they have but which the Centers for Disease Control does not recognize, and which Steere has said is overdiagnosed.

Lyme disease is a complex infection, there are no two ways about it, Steere says. Its an illness that without treatment can occur in stages with different manifestations at each stage. People can have neurologic involvement, they can have cardiac involvement, they can have arthritis. But it does not cause everything. There are advocacy groups that have grown up that attribute a much wider spectrum of illness to Lyme disease than is the case in mainstream medicine.

This article originally appeared in Connecticut Magazine. You can subscribe here , or find the current issue on sale here . Sign up for the newsletter to get the latest and greatest content from Connecticut Magazine delivered right to your inbox. On Facebook and Instagram @connecticutmagazine and Twitter @connecticutmag .

Read the original post:
Lyme disease emerged in CT in the 1970s ... then the conspiracy theories started - CT Insider